Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study
Amulirafusp alfa showed favorable safety profile and preliminary efficacy in patients with r/r B-NHL, meriting further investigation. Trial registration NCT05805943.
Authors
- Zhiming Li (ORCID: https://orcid.org/0000-0001-9730-9917)
- Wenzhi Tian (ORCID: https://orcid.org/0000-0002-1986-4381)
- Qiying Lu
- W Meng (ORCID: https://orcid.org/0009-0003-9336-4419)
- Keshu Zhou (ORCID: https://orcid.org/0000-0001-5467-1377)
- Hongmei Jing (ORCID: https://orcid.org/0009-0002-7352-3964)
- Mingzhi Zhang (ORCID: https://orcid.org/0000-0001-8390-6550)
- Li Yu (ORCID: https://orcid.org/0000-0002-2221-8911)
- Zhen Wang (ORCID: https://orcid.org/0000-0001-9289-4889)
- Yuankai Shi (ORCID: https://orcid.org/0000-0002-3342-4964)
- Jianliang Yang
- Yongping Song
Institutions
- Nanchang University (CN)
- Sun Yat-sen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Zhengzhou University (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- Peking University Third Hospital (CN)
- Henan Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Journal of Hematology & Oncology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s13045-024-01646-2
- Citations
- 8
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- National Science and Technology Major Project